DUBLIN, July 7, 2023 /PRNewswire/ — “Home Diagnostic Testing (COVID-19, FOB, Glucose, HIV and Other Testing) 2023 Markets and Trends” report has been added to ResearchAndMarkets.com offer.
The home in vitro diagnostic (IVD) test market consists of IVD tests that can be purchased at the local store or on the Internet where the patient collects the sample and the results are usually displayed within minutes. Typically, these are lateral flow technology or dip stick methods.
Meanwhile, the global Home IVD testing market is a growing market with a lot of potential. The IVD Home Collection test market consists of test kits that are obtained from the local pharmacy or from the Internet and sent to the patient’s home. The patient collects the sample, places it in a collection container, and sends it to the laboratory for testing. The results are sent to the patient and/or treating physician.
Detailed market estimates by specialty
This report covers the home and home testing markets by segmenting them into different areas, including:
The report also splits the market by location:
A long-standing trend that has seen renewed attention
At-home IVD tests designed for home use are usually available in the form of strips, cassettes, dip cards, and digital monitoring devices. The most commonly used patient self-tests are for pregnancy, ovulation, and glucose. Manufacturers anticipated consumer acceptance of occult blood, cholesterol, HIV, coagulation/PT, and H. pylori tests. Worldwide, these tests have had minimal appeal. The need for a blood sample has limited the use of cholesterol self-tests. Tests like H. pylori haven’t yet captured consumer interest. Outside the United States, consumers will find OTC testing for a wider range of analytes, including allergens, TSH and FSH. The latest trend to overcome reticence for self-testing is towards the consumer marketing of laboratory tests in public places such as shopping malls and supermarkets and home test kits via the Internet.
The forecasted market analysis for 2022-2027 was largely based on demographic trends, new developments, innovative technology and global expansion.
The growth of the Home IVD testing market stems from a paradigm shift among consumers seeking greater control over their healthcare. Since the 1980s, consumers have pushed for access to their lab tests, but that has been slow to evolve due to concern that consumers might try to diagnose themselves without understanding how diagnostic information all fits together.
As the use of the Internet for medical information has increased, consumers have become medical consumers, not just patients. This has created a shift in the doctor/patient relationship as people become more knowledgeable about their health and want more control over their personal information and treatment decisions. Consumers are more cost-conscious, and the rise of high-deductible insurance plans requires people to ask more questions, do their own research, and work with their doctor on medical decisions, tests, and treatments.
Drivers include growing demand for early disease detection and diagnosis, personalized medicine, importance of disease tracking, expanded technologies, and costs.
The forerunner of the Home IVD testing market is based on the rise of genetic testing, which began in the 1970s and has grown to include testing for cancer and other diseases that may run a genetic susceptibility in the family. Ancestral testing has provided clues about what might be in the ancestral pool, prompting consumers to find out more about their susceptibility to certain diseases. The passage of the Genetic Information Nondiscrimination Act (GINA) of 2008 opened the door for consumer awareness of genetic makeup without fear of discrimination from health insurers and employers.
The companies that provide such tests offer a wide range of services, such as the prediction of adverse reactions to specific drugs, the estimation of the susceptibility to various complex diseases and the diagnosis mainly of genetic diseases.
Several trends continue to shape the home laboratory testing market, including growing demand for early disease detection and diagnosis, personalized medicine, importance of disease monitoring, expanded technologies, and costs.
Main topics covered:
Chapter 1: Executive Summary
Chapter 2: Introduction
Chapter 3: IVD testing at home
Chapter 4: Home Collection IVD Testing
Chapter 5: Market Participants
-
23eMe, Inc
-
Diagnostics Abbott
-
AccessBio, Inc.
-
ACON Laboratories, Inc.
-
ARKRAY, Inc.
-
Ascensia Diabetes Care Holding AG
-
Atomic diagnostics
-
Becton-Dickinson
-
binx cheers
-
Biomerica, Inc.
-
Biosynex SA
-
BTNX Inc.
-
Church & Dwight Co. Inc
-
Color Health, Inc.
-
Cue Salute
-
Dexcom, Inc.
-
Easy DNA
-
Always good
-
exact sciences
-
First Check Diagnostics LLC
-
Diagnostics GlysBy
-
Elena laboratories
-
Hemosure, Inc.
-
LifeScan, Inc
-
Medichecks.com Ltd.
-
Myriad Genetics, Inc.
-
OraSure Technologies, Inc.
-
Polymedco, Inc
-
Preventis GmbH
-
Prima Lab SA
-
Quidel Ortho Corporation
-
Roche Diagnostic Corporation
-
Siemens Healthineers GmbH
-
Swiss Precision Diagnostics GmbH
-
Health trivia
-
VedaLab
Chapter 6: Market analysis
For more information about this report, please visit https://www.researchandmarkets.com/r/nyee77
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source of international market research reports and market data. We bring you the latest data on international and regional markets, key industries, top companies, new products and the latest trends.
Media contact:
Research and Markets
Laura WoodChief director
press@researchandmarkets.com
For EST office hours call +1-917-300-0470
For US/CAN Toll Free Call +1-800-526-8630
For GMT office hours call +353-1-416-8900
US Fax: 646-607-1907
Fax (outside the US): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
View Original Content: https://www.prnewswire.com/news-releases/assessment-of-the-at-home-diagnostic-testing-global-markets-2023-2027–leading-players-are-abbott- roche-siemens–23andme-301871905.html
SOURCE Research and markets
#Assessment #Global #Home #Diagnostic #Testing #Markets #Major #players #Abbott #Roche #Siemens #23andMe
Image Source : finance.yahoo.com